Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open‐label, multicenter, Phase IIIb study
Authors:
- Alan MenterAMAlan Menter
- (for the Efalizumab Study Group)(G(for the Efalizumab Study Group)
- 5 June 2007
- journal article
- research article
- Published by Wiley in International Journal of Dermatology
- Vol. 46 (6) , 637-648
Abstract
Background Rebound in psoriasis is, by definition, a rapid worsening of disease following the discontinuation of therapy for psoriasis; it occurs following the abrupt discontinuation of many therapies. To prevent rebound on discontinuation of efalizumab, this study evaluated the effectiveness of transitioning patients to an alternative psoriasis therapy.Methods Patients (n = 130) received subcutaneous efalizumab 1 mg/kg/week for 12 weeks. Efalizumab was discontinued at 12 weeks; patients were evaluated for improvement from baseline in the Psoriasis Area and Severity Index (PASI) and a 12‐week transition period was begun. Patients who achieved PASI improvement of 75% or more (PASI‐75) at week 12 of efalizumab treatment were observed during the transition period and treated only if psoriasis recurred. Patients who did not attain PASI‐75 at week 12 of efalizumab treatment were immediately transitioned to an alternative psoriasis therapy at the physician's discretion. All patients were evaluated for signs of rebound following efalizumab discontinuation.Results Rebound was not observed in any PASI‐75 responder (n = 46). Rebound was observed in two of 32 patients who achieved between PASI‐50 and PASI‐75, and was more common in nonresponders (14/49). Rebound was observed in none of the eight patients treated with cyclosporine and in two of the 12 patients treated with methotrexate during the transition period.Conclusions These results suggest that efalizumab‐responsive patients are less likely to experience rebound than nonresponders and may not require treatment until disease recurrence following efalizumab discontinuation. Efalizumab nonresponders are at higher risk of developing rebound and thus should be considered for transition to an appropriate psoriasis therapy immediately following efalizumab discontinuation.Keywords
This publication has 19 references indexed in Scilit:
- Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trialJournal of the American Academy of Dermatology, 2006
- Relapse, rebound, and psoriasis adverse events: An advisory group reportJournal of the American Academy of Dermatology, 2006
- British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005British Journal of Dermatology, 2005
- Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trialJournal of the American Academy of Dermatology, 2005
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisJournal of the American Academy of Dermatology, 2004
- Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasisJournal of Dermatological Treatment, 2003
- "New treatments and old problems."Journal of Dermatological Treatment, 2003
- An approach to the treatment of moderate to severe psoriasis with rotational therapyJournal of the American Academy of Dermatology, 1993
- Guidelines for management of patients with psoriasis. Workshop of the Research Unit of the Royal College of Physicians of London; Department of Dermatology, University of Glasgow; British Association of Dermatologists.BMJ, 1991
- Methotrexate in psoriasis: Revised guidelinesJournal of the American Academy of Dermatology, 1988